Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on December 12, 2006. The filing discloses a material corporate event: the execution of an underwriting agreement for a public offering of common stock.
Key Financial Metrics
The filing details a capital raise transaction rather than operational financial performance. Key transaction metrics include:
- Shares Issued: 4,700,000 shares of Common Stock.
- Public Offering Price: $22.00 per share.
- Price to Company: $21.57 per share.
- Underwriter: Banc of America Securities LLC.
- Registration: Pursuant to Form S-3 (File No. 333-138586) filed November 9, 2006.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital resulting from the sale of 4,700,000 shares. This transaction represents a significant financing event intended to provide the company with additional working capital.
Guidance, Outlook, and Risks
The filing does not contain specific management guidance, future outlook, or a discussion of risks and contingencies beyond the standard disclosure of the underwriting agreement. The transaction was announced via a press release attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the final closing date and total net proceeds received after underwriting discounts.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific terms, conditions, and lock-up provisions.
- Confirm the impact of this equity issuance on existing shareholder dilution.
- Check subsequent filings for the actual use of proceeds as disclosed in the press release.